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Cholesterol metabolism is closely interrelated with
cardiovascular disease in humans. Dietary supple-
mentation with omega-6 polyunsaturated fatty acids
including arachidonic acid (AA) was shown to favor-
ably affect plasma LDL-C and HDL-C. However, the
underlying mechanisms are poorly understood. By
combining data from a GWAS screening in >100,000
individuals of European ancestry, mediator lipido-
mics, and functional validation studies in mice, we
identify the AAmetabolome as an important regulator
of cholesterol homeostasis. Pharmacological modu-
lation of AA metabolism by aspirin induced hepatic
generation of leukotrienes (LTs) and lipoxins (LXs),Cell Mthereby increasing hepatic expression of the bile
salt export pump Abcb11. Induction of Abcb11 trans-
lated in enhanced reverse cholesterol transport, one
key function of HDL. Further characterization of the
bioactive AA-derivatives identified LX mimetics to
lower plasma LDL-C. Our results define the AA me-
tabolome as conserved regulator of cholesterolmeta-
bolism, and identify AA derivatives as promising ther-
apeutics to treat cardiovascular disease in humans.
INTRODUCTION
Atherosclerosis is still the leading cause of death in industrialized
countries, and novel therapies to lower low-density lipoproteinetabolism 20, 787–798, November 4, 2014 ª2014 The Authors 787
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Arachidonic Acid Metabolome and Cholesterolcholesterol (LDL-C) are urgently needed. Additionally, any
approach promoting the transport of excess cholesterol from
plaque macrophages back to the liver via plasma high-density li-
poprotein (HDL) for biliary and final fecal excretion is expected to
prevent atherosclerosis, a mechanistic concept called reverse
cholesterol transport (RCT) (Cuchel and Rader, 2006; Degoma
and Rader, 2011; Rader and Daugherty, 2008). It is well known
that dietary supplementation with omega-6 polyunsaturated
fatty acids (omega-6 PUFAs) including arachidonic acid (AA) re-
duces the risk of cardiovascular disease (CAD) (Harris et al.,
2009; Katan, 2009), which is in part attributable to the observa-
tion that increased AA plasma levels are associated with benefi-
cial changes in LDL-C and HDL-C.
In humans, AA is metabolized into many potent bioactive com-
pounds, such as (1) prostaglandins (PGs) and thromboxanes
(TXs), (2) leukotrienes (LTs), and (3) lipoxins (LXs). Whereas PGs
and TXs are formed by cyclooxygenases I and II (COX I/II), LTs
are generated through the action of arachidonate 5-lipoxygenase
(ALOX5), and LXs—an acronym of lipoxygenase interaction prod-
uct—by the sequential cell-cell interaction of different lipoxyge-
nases (McMahon and Godson, 2004; Serhan, 2007): LTA4, the
intermediate of LT synthesis, is produced in neutrophils via
ALOX5 and can be taken up by platelets and converted into LXs
via ALOX12. 15S-Hydroxyeicosatetraenoic acid (15S-HETE) is
synthesized in epithelial cells and monocytes via ALOX15, which
can be further converted into LXs in leukocytes by ALOX5. Gener-
ation of LXs occurs alsowhen 15-HETE accumulates in cell mem-
branes of neutrophils, where it is converted into LXs (McMahon
and Godson, 2004; Serhan, 2007). An additional route of LX
biosynthesis emerges in cells exposed to aspirin. Aspirin acety-
lates COX II, changing its activity to a lipoxygenase. This gener-
ates 15R-HETE, which is finally converted into 15-epi-lipoxins
via ALOX5 (McMahon and Godson, 2004; Serhan, 2007).
To date, the relative pathophysiological roles of lipoxyge-
nases, LTs, and LXs have been extensively studied in inflamma-
tion where LTB4 exerts proinflammatory actions by promoting
the recruitment of leukocytes to the site of insult. This is followed
by an increase in anti-inflammatory eicosanoids LXA4 and its
regioisomer LXB4, which mediate resolution of inflammation
(Serhan, 2007). One important example of sustained chronic
inflammation and failure of its resolution is found in atheroscle-
rosis. It was proposed that any intervention leading to an in-
crease in proresolving LXs may represent a novel therapeutic
approach to interrupt the vicious circle of inflammation taking
place in the arterial wall (Spite and Serhan, 2010). Aspirin consti-
tutes such a pharmacological approach. Aspirin is a widely used
drug for primary and secondary prevention of myocardial infarc-
tion, stroke, and unstable angina. By transforming the enzymatic
properties of COX II into that of a lipoxygenase, aspirin was
shown to increase the generation of LXs not only in different an-
imal models of chronic inflammation, but also in humans, thereby
inhibiting the accumulation of leukocytes at sites of inflammation
(Spite and Serhan, 2010).
Intriguingly, evidence from genome-wide association studies
(GWASs) revealed a robust association between single nucleo-
tide polymorphisms (SNPs) of ALOX5 and of 5-lipoxygenase
activating protein (FLAP) with the risk of myocardial infarction,
obesity, and stroke (Helgadottir et al., 2004; Mehrabian et al.,
2005; Peters-Golden and Henderson, 2007). Confirmation from788 Cell Metabolism 20, 787–798, November 4, 2014 ª2014 The Autindependent studies is, however, warranted to fully support the
genetic association between ALOX5 and CAD.
So far, neither the relative role of different AA-metabolizing en-
zymes, including lipoxygenases, nor the potential impact of their
main metabolites, i.e., LTB4 and LXs, on cholesterol metabolism
has been systematically investigated. Here, we elucidate the
relative roles of LTs and LXs on cholesterol homeostasis by
combining data fromGWAS analysis in humans, mediator lipido-
mics, and loss-of-function studies in mice. We identify LX mi-
metics as promising therapeutics to lower plasma LDL-C and
to treat atherosclerosis.
RESULTS
Identification of ALOX5 as Regulator of HDL-C
in Humans
We first mined published genome-wide association data for sig-
nals in and around genes encoding enzymes involved in the
metabolism of AA. Using the recently published data of 46
GWASs on the relevance of novel genetic loci for blood lipids
in >100,000 individuals of European ancestry (Teslovich et al.,
2010), we evaluated whether common variants in the human cy-
clooxygenases I and II (PTGS1 and PTGS2), ALOX5, ALOX12,
and the ALOX15 gene loci were associated with alterations in
plasma cholesterol levels. We found no association of plasma
cholesterol levels to variants within or around the PTGS1,
PTGS2, ALOX12, and ALOX15 genes (data available upon
request), whereas robust association signals were observed to
variants within the chromosome 10 locus (10q11.21) containing
both the ALOX5 and MARCH8 genes (see Figure S1 available
online), which was confirmed in the 2013 GLGC data set
comprising >188,000 individuals (Willer et al., 2013) (Figure S2).
Figure 1A shows the signals over the ALOX5 gene associated
with HDL-C, with the ten most significant SNPs within the gene
listed in Table S1. No significant associations with LDL-C were
observed at this locus, and signals for total cholesterol seem
driven by the HDL-C associations. Of note, individuals carrying
the common T allele (allele frequency of 0.65) of lead SNP
rs12765320 within the ALOX5 gene showed a dose-dependent
decrease in plasma HDL-C levels (ES = 0.429 mg dl1 per
copy of T allele; Figure 1B). The reported association of
rs12765320 with HDL-C in the GWAS study was independently
replicated in the smaller LUdwigshafen RIsk and Cardiovascular
Health (LURIC) (Winkelmann et al., 2001) cohort comprising
2,095 individuals (HDL-C 37.23 ± 10.69 mg dl1 versus 36.32 ±
9.42mg dl1, male homozygous carriers of the CC and the TT al-
leles, respectively; p < 0.05).
To further support the association between ALOX5 and
HDL-C, a second SNP (rs7068039) belonging to the haplotype
block (Table S1) was genotyped in 2,141 individuals from the
PLIC (Progressione Della Lesione Intimale Carotidea) study (Nor-
ata et al., 2010). Homozygous carriers of the common TT allele
presented significantly lower levels of HDL-C compared to ho-
mozygous CC carriers (55.11 ± 14.87 mg dl1 versus 58.78 ±
13.88 mg dl1, respectively; p < 0.05) (Figure 1C), thus repli-
cating this association in a second independent cohort. Next,
we characterized whether the differences in HDL-C levels
also translate into alterations of HDL function. Therefore, choles-
terol efflux capacity of apoB- depleted serum from age- andhors
Figure 1. Identification of ALOX5 as Regu-
lator of HDL-C in Humans
Common variants in the human ALOX5 gene were
evaluated in a GWAS meta-analysis comprising
>100,000 individuals of European ancestry.
(A) Manhattan plot for GWA to HDL-C in the
ALOX5 gene, with values of –log10 p plotted
against position on chromosome 10; colors indi-
cate amount of linkage disequilibrium between
SNPs; diamonds indicate the identified lead SNPs
rs12765320 and rs7068039 within ALOX5. Plots
were generated using LocusZoom.
(B) Per allele HDL-C relative change in carriers of
the lead ALOX5 SNP rs12765320 as derived from
the GLGC data set.
(C) Per allele HDL-C relative change in carriers of
the lead ALOX5 SNP rs7068039 in the PLIC repli-
cation cohort.
(D) Cholesterol efflux using apoB-depleted serum
from 30 CC and 30 TT age- and sex-matched
rs7068039. Graphs show mean ± SEM, *p < 0.05.
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Homozygous TT allele carriers showed significantly reduced
cholesterol efflux capacity compared to CC carriers (Figure 1D).
In summary, GWAS screening in humans helped to identify asso-
ciations between variants within ALOX5 not only with HDL-C
mass but importantly also with HDL function.
Aspirin Treatment Promotes RCT
From the GWAS data it cannot be inferred whether the newly
identified variants may regulate expression of arachidonate lip-
oxygenases and whether differential activation of arachidonate
lipoxygenases may impact plasma cholesterol levels or affect
functional properties of lipoproteins such as RCT. Therefore,
we performed functional validation studies in mice using a sys-
tematic approach: (1) simultaneous activation of Alox5 and
Alox12/15, (2) selective knockout of Alox5, and (3) knockout of
Alox12/15. In contrast to humans, who express at least four iso-
forms of ALOX15, mice do not have separate 12- and 15-arach-
idonate lipoxygenases, but rather a combined 12/15-lipoxyge-
nase with variable positional specificity for both the 12-position
and the 15-position of AA (Ku¨hn and O’Donnell, 2006).
In our first in vivo experiments, we simultaneously induced the
processing of AA by Alox5 and Alox12/15 through pharmacolog-
ical inhibition of Cox I/II, which shifts the biosynthetic pathways of
the AA metabolome toward the formation of LXs and LTs in mu-
rine systems (Figure 2A) (Brink et al., 2003; Serhan, 2007; Spite
and Serhan, 2010). Inhibition of Cox I/II in mice was achieved
by systemic treatment with aspirin (Tancevski et al., 2006), and
in vivo macrophage-to-feces RCT studies were performed as
described (Tancevski et al., 2010; Zhang et al., 2003): after intra-
peritoneal injection of [3H]-cholesterol-labeled J774 macro-
phages, the tracerwasmeasured in plasmaand feces (Figure2B).
Aspirin-treated mice had significantly decreased plasma [3H]-
cholesterol levels 24 hr postinjection (Figure 2C), which wasCell Metabolism 20, 787–798,associated with significantly increased
[3H]-sterol levels in feces (Figure 2D).
These findings suggested that the in-
crease in fecal tracer content has beencaused either by enhanced uptake of [3H]-HDL-C into liver and/
or by increased biliary transport of sterols. Hepatic protein
expression of the HDL receptor (scavenger receptor BI, SR-BI)
and of the LDL receptor (LDLr) were unaffected in aspirin-treated
mice (Figure S3A), making the hypothesis of enhanced choles-
terol clearance from plasma rather unlikely. Accordingly, plasma
total cholesterol levels as well as HDL-C levels were unchanged
in aspirin-treated mice (Figures S3B and S3C), which was further
confirmed by lipoprotein separation analysis via fast protein liquid
chromatography (FPLC) (Figure 2E).
Aspirin Promotes Excretion of Bile Acids
In the liver, a major part of cholesterol is converted into bile acids
(Lefebvre et al., 2009), which are secreted into bile for eventual
removal via feces (Lefebvre et al., 2009; Stieger, 2009; Zollner
and Trauner, 2009). To better define the type of sterols found
to be increased in feces of aspirin-treated mice, a subsequent
RCT study was performed, and fecal sterols were extracted
into neutral and acidic sterols. We found a marked increase in
[3H]-acidic sterols, i.e., bile acids, underlying the observed in-
crease in total counts (relative content of fecal [3H]-acidic sterols,
78% versus 94%, control versus aspirin-treated mice, p <
0.001). Accordingly, in an independent in vivo experiment, Cox
I/II inhibition by aspirin was shown to increase the content of
fecal bile acid mass per se, as measured by an enzymatic assay
(Figure 2F). Plasma levels of 7a-hydroxy-4-cholesten-3-one
(C4), a stable plasma marker of bile acid synthesis (Ga¨lman
et al., 2003), were not different between aspirin-treated and con-
trol mice (Figure S4). In line with unaffected C4 plasma levels,
there was no change in hepatic Cyp7a1 mRNA expression, the
rate-limiting enzyme for conversion of cholesterol into bile acids
(Figure 2G). Moreover, quantitative real-time PCR with reverse
transcription (qRT-PCR) analysis revealed no changes in
mRNA levels of hepatic neutral sterol transporters Abcg5 andNovember 4, 2014 ª2014 The Authors 789
Figure 2. Aspirin Promotes RCT
(A) Inmice, AA can bemetabolized via threemain pathways: (1) Cox I/II-mediated generation of prostaglandins and thromboxane (PG2, TXA2); (2) Alox5-mediated
generation of leukotriene B4 (LTB4) and cysteinyl-leukotrienes; and (3) Alox12/15- and Alox5-mediated generation of lipoxins A4 and B4 (LXA4, LXB4). To inhibit
Cox I/II, thereby shifting the AA metabolism to Alox5 and Alox12/15 pathways, C57BL/6 mice were treated with aspirin in their drinking water for 7 days.
(B) For macrophage-to-feces RCT studies, control and aspirin-treated mice were injected intraperitoneally with cholesterol-loaded, [3H]-labeled J774 macro-
phages (F). The tracer was measured in plasma at indicated time points and in fecal sterols collected for 48 hr.
(C and D) (C) Plasma [3H]-cholesterol levels and (D) fecal [3H]-sterol levels (n = 6–10, data representative of three independent macrophage-to-feces RCT
experiments).
(E) FPLC analysis of plasma pooled from control and aspirin mice (n = 6).
(F) Enzymatic measurement of bile acids in feces collected for 48 hr (n = 7).
(G) qRT-PCR measurement of neutral sterol transporters Abcg5 and Abcg8, and bile acid converting enzyme Cyp7a1 in livers of mice (n = 7).
(H and I) (H) Immunoblot analysis of bile acid secreting pump Abcb11 and (I) Abcc2 protein expression in livers of mice (n = 4–5, bars represent densitometric
quantification normalized to actin).
(J) [14C]-glycocholic acid was injected into the tail vein of mice, and after 30 min the tracer was quantified in total bile (n = 5).
(K) Plasma [3H]-cholesterol levels at indicated time-points and (L) fecal [3H]-sterol levels (0–48 hr) from a macrophage-to-feces RCT study performed in
Abcb11/ mice (n = 4–5).
(M) Atheroregression in LDLr/ mice treated with aspirin. Graphs show mean ± SEM (n = 6), #p = 0.062, *p < 0.05, ***p < 0.001.
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Abcb11 protein levels in livers of aspirin-treatedmice (Figure 2H),
which constitutes a major determinant of bile flow. On the apical
membrane of hepatocytes resides not only Abcb11 but also the
multidrug resistance-associated protein 2 (Mrp2 or Abcc2),790 Cell Metabolism 20, 787–798, November 4, 2014 ª2014 The Autcapable of promoting bile acid excretion (Zollner and Trauner,
2009). Abcb11 mediates excretion of monovalent bile acids,
whereas divalent bile acids are exported by Abcc2, which is a
conjugate export pump and which has also been discussed as
an alternative canalicular bile acid export system in mice (Zollnerhors
Figure 3. The Impact of Aspirin Treatment on the AA Metabolome
(A) qRT-PCR analysis of Cox1, Cox2, Alox5, Alox12, Alox15 in livers of control and of aspirin-treated C57BL/6 mice (n = 6–7), **p < 0.01.
(B) Mediator lipidomics in livers of control and of aspirin-treated C57BL/6 mice (n = 5). Graphs show mean ± SEM.
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were found strongly decreased in livers of aspirin-treated mice
(Figure 2I). Under physiological conditions, Abcb11 constitutes
the rate-limiting step in bile acid transport from the liver into
the bile and subsequently intestine (Figge et al., 2004; Stieger,
2009; Stieger and Beuers, 2011; Zollner and Trauner, 2009),
and its transgenic overexpression in mice increases bile flow
by 30% and fecal bile acid content by more than 40% (Wang
et al., 2010). To firmly establish that Cox I/II inhibition by aspirin
increases bile acid excretion, [14C]-glycocholic acid was injected
into the tail vein of mice, and after 30 min the tracer was quanti-
fied in gall bladders of control and aspirin-treated animals (Wang
et al., 2001). In confirmation of our data, Cox I/II inhibition by
aspirin increased the amount of tracer in bile 2-fold (Figure 2J).
Finally, treatment of Abcb11/ mice with aspirin had no effect
on macrophage-to-feces RCT (Figures 2K and 2L), proving the
hypothesis of an Abcb11-dependent mechanism. Thus, we
conclude that Cox I/II inhibition by aspirin promotes fecal excre-
tion of bile acids and thereby the rate of macrophage-to-feces
RCT in mice by increasing hepatic Abcb11 expression.
Aspirin Induces Regression of Atherosclerosis in
LDLr–/– Mice
Aspirin is one of the most widely used drugs for primary and sec-
ondary prevention of CAD, prescribed to patients at high cardio-Cell Mvascular risk (i.e., diagnosed with CAD, diabetics, etc.). So far,
the atheroprotective effect of aspirin was related to its antithrom-
botic and anti-inflammatory/proresolving properties (Spite and
Serhan, 2010). However, the identification of aspirin as a RCT-
promoting drug also raised the question of whether aspirin could
confer regression of established atherosclerosis. For this pur-
pose, we performed a study in male LDLr/ mice fed a west-
ern-type diet for 14 weeks, then switched to normal chow and
divided into two groups, one receiving placebo and the other
receiving aspirin in the drinking water for another 6 weeks.
Aspirin treatment led to an 50% reduction in atherosclerotic
lesion size, showing that aspirin can lead to the regression of
atherosclerosis (Figure 2M).
Lipidomic Profiling of Aspirin-Treated Mice
To verify adequate Cox I/II inhibition by aspirin and to analyze
changes in intrahepatic levels of LTs and LXs, we next per-
formed qRT-PCR analysis of the genes involved in the
biogenesis of these lipids followed by mediator lipidomic
analysis (Arita, 2012; Morita et al., 2013). As shown in Fig-
ure 3A, and in line with a previous report (Xu et al., 1999),
livers of aspirin-treated C57BL/6 mice had reduced Cox2
expression, whereas the expression of arachidonate lipoxy-
genases was unaffected by aspirin treatment. Aspirin is ex-
pected to inhibit Cox I activity, thereby blocking the formationetabolism 20, 787–798, November 4, 2014 ª2014 The Authors 791
Figure 4. Leukotrienes and Lipoxins Regulate Abcb11 in a Posttranslational Fashion
To investigate the mechanisms underlying Abcb11 regulation by aspirin, studies in primary murine hepatocytes derived from C57BL/6 mice were
performed.
(A and C–E) Hepatocytes were incubated with indicated compounds at given concentrations for 24 hr, after which Abcb11 protein expression was measured by
immunoblot analysis. Additionally, protein expression of SR-BI and LDLr was analyzed; actin served as loading control.
(B) Heatmap showing relative changes of TXB2, LTB4, and LXA4 levels in livers and hepatocytes measured by means of mediator lipidomics (aspirin/control).
(F) FXR reporter assay with positive control (GW4064), LXB4, and LTB4 used at indicated concentrations.
(G) qRT-PCR analysis of Abcb11 in primary murine hepatocytes treated with vehicle or aspirin (100 mM) for 6 and 12 hr.
(H) TomeasureAbcb11mRNA degradation, murine hepatocytes were pretreated with actinomycin D (Act. D), after which they were treated with vehicle or aspirin
(100 mM) for 24 hr. RNA levels were measured by qRT-PCR, ***p < 0.001.
(I) Protein translation in murine hepatocytes was inhibited by preincubation with cycloheximide (10 mg ml1) for 6 hr, after which cells were treated with vehicle,
LTB4 (50 nM), and LXB4 (10 nM) for another 18 hr. Immunoblot showing Abcb11 expression; actin served as loading control.
(J) Primary murine hepatocytes were coincubated with MAPK p38 ihibitor SB 203580 (10 mM) and vehicle, LTB4 (50 nM), and LXB4 (10 nM) for 24 hr, after which
immunoblot analysis of Abcb11 was performed. Actin served as loading control.
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profiling, as levels of the metabolite of TXA2, namely TXB2,
were dramatically reduced in livers of aspirin-treated mice
(Figure 3B). Finally, lipidomic profiling revealed that inhibition
of the Cox I/II pathway led to enhanced generation of both
LTs (LTB4) and LXs (LXA4) in livers of aspirin-treated animals
(Figure 3B). We thus reasoned that the observed increase in
hepatic Abcb11 protein expression in mice treated with
aspirin may have been conferred by either LTs or LXs, or
both.792 Cell Metabolism 20, 787–798, November 4, 2014 ª2014 The AutLeukotrienes and Lipoxins Regulate Abcb11, SR-BI, and
LDLr in Hepatocytes
Using primary murine hepatocytes derived from C57BL/6 mice,
we confirmed our in vivo studies by demonstrating that both
aspirin and its active metabolite salicylic acid induce Abcb11
protein expression. Moreover, aspirin and salicylic acid induced
SR-BI protein expression, whereas they downregulated the
expression of the LDLr in vitro (Figure 4A). Presently, little is
known about lipoxygenase pathways within hepatocytes. One
main difference between hepatocytes and other cell types ishors
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lab showed that Kupffer cells, which are ofmyeloid origin and ex-
press high levels of Alox5, are the major source of LTB4 and LXs
in rat liver exposed to aspirin (Planaguma` et al., 2002). Accord-
ingly, when comparing mediator lipidomic profiles of mouse liver
and of isolatedmurine hepatocytes, we found that (1) in both set-
tings, aspirin dramatically reduced TXB2 levels as result of effi-
cient Cox I inhibition, (2) in liver extracts, aspirin treatment
increased both LTs and LXs, and (3) in isolated mouse hepato-
cytes, aspirin treatment increased only LX formation (Figure 4B).
When analyzing the relative effects of different LX isomers on
Abcb11 expression, we found that LXA4, 15-epi-LXA4, and
LXB4 increased Abcb11 at 10 nM, with LXB4 showing the stron-
gest induction (Figure 4C). Dose-titration studies as well as
coincubation experiments with LTB4 and LXB4 in primary hepa-
tocytes derived from C57BL/6 mice revealed that both lipid
mediators increase Abcb11 expression. Intriguingly, LXB4 de-
creased Abcb11 protein expression at high dosages. On the
other hand, SR-BI and LDLr protein expression was induced
mainly by LTB4 (Figures 4D and 4E).
Leukotrienes and Lipoxins Regulate Abcb11 in a
Posttranslational Fashion
To further decipher the molecular mechanisms underlying the
induction of Abcb11 by aspirin, we performed further studies in
primary hepatocytes. The main positive regulator of Abcb11
expression is the transcription factor farnesoid X receptor (Fxr)
(Stieger, 2009; Zollner and Trauner, 2009). However, FXR re-
porter studies ruled out any direct activation of this nuclear re-
ceptor by both LTB4 and LXB4 (Figure 4F). In linewith this finding,
LTs and LXs neither induced the transcription of Abcb11 mRNA
(Figure 4G), nor did they influence Abcb11 mRNA degradation
(Figure 4H). In addition, blocking protein translation by cyclohex-
imide did not abolish Abcb11 protein expression induced by ei-
cosanoids, suggesting that neosynthesis of protein was not
required and that a direct regulation was taking place at a post-
translational level (Figure 4I).
Abcb11 protein expression is known to be stabilized by the
mitogen-activated protein kinase (MAPK) p38 (Kubitz et al.,
2004), and aspirin, in turn, is known to activate p38 in different
cell types, including hepatocytes (Oshima et al., 2008; Trujillo-
Murillo et al., 2008). As shown in Figure 4J, blockage of p38 by
the selective inhibitor SB 203580 abolished the induction of
Abcb11 protein expression by LTB4 and LXB4. To summarize,
LTs and LXs increase the expression of Abcb11 by a posttran-
scriptional and posttranslational mechanism, involving the activ-
ity of MAPK p38.
The Role of Alox5 in Cholesterol Metabolism and RCT
Next, we wondered whether knocking out Alox5 would affect
hepatic Abcb11 expression, cholesterol homeostasis, and
RCT in mice (Figure 5A). As shown in Figure 5B, no marked dif-
ference in plasma LDL-C and HDL-C between Alox5+/+ and
Alox5/mice was observed, whereas VLDL-C levels increased
in the knockouts. In macrophage-to-feces RCT experiments,
Alox5/ mice showed reduced plasma tracer levels over
48 hr (Figure 5C) but no significant change in fecal excretion
of [3H]-sterols, when compared to Alox5+/+ mice (Figure 5D).
Immunoblot analysis revealed an 2-fold induction of hepaticCell MAbcb11 and a moderate increase in SR-BI, but no effect on
LDLr protein expression (Figure 5E). Finally, lipidomic profiling
of livers from Alox5+/+ and Alox5/ mice showed no changes
in LX levels, whereas LTB4 levels were drastically reduced
(Figure 5F).
The Role of Alox12/15 in Cholesterol Metabolism and
RCT
Lack of Alox12/15 in Alox12/15/mice neither affected plasma
cholesterol levels nor influenced macrophage-to-feces RCT,
when compared to Alox12/15+/+ mice (Figures 6A–6D). Accord-
ingly, no change in expression of hepatic Abcb11, LDLr, and
SR-BI was observed in Alox12/15/mice (Figure 6E). Mediator
lipidomic analysis showed unchanged levels of LXs in livers of
Alox12/15/ mice compared to Alox12/15+/+ mice, whereas
LTB4 levels were increased in the knockouts (Figure 6F).
Treatment with Lipoxin Mimetics Lowers Plasma LDL-C
Finally, in an approach to translate our combined findings from
GWAS analysis in humans, mediator lipidomics and functional
studies in mice into the identification of novel compounds which
beneficially influence plasma cholesterol levels and thus puta-
tively the course of CAD, we reasoned to study the impact of sys-
temic treatment with LXB4 on cholesterol metabolism in mice
(Figure 7A). Because LXB4 is unstable and rapidly inactivated
within the circulation, we performed daily i.v. injections into
mice with synthetic stable analogs of LXB4 including 5-(R/S)-
methyl-LXB4 and 8,9-acetylenic-LXB4, the latter being a log or-
der of magnitude less potent than LXB4 (Maddox et al., 1998).
After 4 days of treatment, 8,9-acetylenic-LXB4 caused a nonsig-
nificant 15% decrease in plasma total cholesterol, whereas
5-(R/S)-methyl-LXB4 significantly reduced plasma cholesterol
levels by 30% (Figure 7B). FPLC analysis showed a decrease
in LDL-C in 5-(R/S)-methyl-LXB4-treated mice, whereas HDL-C
remained unchanged (Figure S5). Accordingly, treatment with
5-(R/S)-methyl-LXB4 was associated with an 3-fold increase
in the protein expression of hepatic LDLr and a moderate in-
crease in hepatic protein levels of SR-BI (Figure 7C). Abcb11
protein expression was decreased in animals treated with LXmi-
metics compared to controls.
DISCUSSION
Lipoxygenases are lipid peroxidizing enzymes belonging to the
nonheme iron dioxygenases family and are conserved across
species including bacteria, algae, plants, fish, amphibia, reptilia,
and mammals. In animals, the conventional nomenclature clas-
sifies lipoxygenases according to their positional specificity of
AA oxygenation (Ivanov et al., 2010). Human arachidonate 5-lip-
oxygenase thus catalyzes oxidation of AA at the 5-position, lead-
ing to the formation of hydroxyeicosatetraenoic acids, which can
be further metabolized into LTs and LXs through cell-cell interac-
tion. Leukocytes—well-appreciated players in atherosclerosis
and myocardial infarction (Drechsler et al., 2010; Dutta et al.,
2012)—represent a main source of ALOX5-derived lipid media-
tors under pathophysiological conditions such as sustained
inflammation in atherosclerosis (Spite and Serhan, 2010). Thus
ALOX5 is believed to potentially accelerate atherosclerosis by
promoting the inflammatory process within the arterial walletabolism 20, 787–798, November 4, 2014 ª2014 The Authors 793
Figure 5. The Role of Alox5 in Abcb11 Regulation and Cholesterol Homeostasis
(A) To selectively study the Alox5 pathway, studies in Alox5+/+ and Alox5/ mice were performed.
(B) FPLC analysis of plasma pooled from Alox5+/+ and Alox5/ mice (n = 5).
(C) Plasma [3H]-cholesterol levels at indicated time points and (D) fecal [3H]-sterol levels (0–48 hr) from a macrophage-to-feces RCT study performed in Alox5+/+
and Alox5/ mice (n = 3).
(E) Immunoblot analysis of LDLr, SR-BI, and Abcb11 protein expression in livers of mice (n = 4; bars represent densitometric quantification normalized to actin).
Graphs show mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
(F) Mediator lipidomics in livers of Alox5+/+ and Alox5/ mice (n = 3). Graphs show mean ± SEM.
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and Henderson, 2007). Here, we extend this knowledge by
showing thatALOX5SNPs associatewith HDL-Cmass and func-
tion in human plasma. During the last decade, the old paradigm
focusing solely on HDL-C levels as predictor of atherosclerosis
changed to a more comprehensive, functional view of HDL parti-
cles. In this regard, it was shown that one key function of HDL
particles, namely cholesterol efflux capacity from macrophages,
has a strong inverse association with atherosclerosis that is inde-794 Cell Metabolism 20, 787–798, November 4, 2014 ª2014 The Autpendent of HDL-C levels (Khera et al., 2011). Simultaneously,
macrophage-to-feces RCT became a recognized key function
of HDL important for regression of atherosclerosis (Cuchel and
Rader, 2006). Rader and others identified amultitude of novel ap-
proaches to promote RCT, including transgenic overexpression
of SR-BI or apo-AI, apo-AI-directed therapeutics, and Lxr and
Ppara activation (Rosenson et al., 2012). Moreover, biliary sterol
secretion was recognized to be required for functional macro-
phage-to-feces RCT (Nijstad et al., 2011). Here, we show thathors
Figure 6. The Role of Alox12/15 in Abcb11 Regulation and Cholesterol Homeostasis
(A) To selectively study the Alox12/15 pathway, studies in Alox12/15+/+ and Alox12/15/ mice were performed.
(B) FPLC analysis of plasma pooled from Alox12/15+/+ and Alox12/15/ mice (n = 5).
(C) Plasma [3H]-cholesterol levels at indicated time points and (D) fecal [3H]-sterol levels (0–48 hr) from a macrophage-to-feces RCT study performed in
Alox12/15+/+ and Alox12/15/ mice (n = 5).
(E) Immunoblot analysis of LDLr, SR-BI, and Abcb11 protein expression in livers of mice (n = 4–5; bars represent densitometric quantification normalized to
albumin). Graphs show mean ± SEM.
(F) Mediator lipidomics in livers of Alox12/15+/+ and Alox12/15/ mice (n = 3). Graphs show mean ± SEM.
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atherosclerosis, promotes macrophage-to-feces RCT by in-
creasing fecal excretion of bile acids. Moreover, we found that
aspirin induces regression of established atherosclerosis in
mice, which may—besides its well-known anti-inflammatory
and platelet-inhibitory effects—be at least in part due to promo-
tion of RCT.
We identify Abcb11 to be upregulated upon aspirin treatment.
Analysis of bile acid kinetics, together with macrophage-to-Cell Mfeces RCT measurement in Abcb11/ mice, showed that pro-
motion of bile flow is the driving force of RCT in mice treated
with aspirin. Failure of aspirin to increase RCT in Abcb11/
mice is conceivably due to the lack of Abcb11, which, however,
cannot be definitively ruled out, because there may be other hy-
pothetic compensatory mechanisms. Intriguingly, by the help of
lipid mediator profiling we found that both Alox5-dependent
classes of lipids, namely LTs and LXs, induce protein expression
of Abcb11 in a posttranslational fashion, presumably byetabolism 20, 787–798, November 4, 2014 ª2014 The Authors 795
Figure 7. Treatment with Lipoxin Mimetics
Lowers Plasma LDL-C
(A) C57BL/6 mice were daily injected i.v. with
vehicle (control), 10 ng 8,9-acetylenic-LXB4, or
10 ng 5-(R/S)-methyl-LXB4 for 4 days (data pre-
sented are representative of three independent
experiments).
(B) Plasma total cholesterol measurement in con-
trol and 8,9-acetylenic-LXB4- and 5-(R/S)-methyl-
LXB4-treated mice (n = 3).
(C) Immunoblot analysis of LDLr, SR-BI, and
Abcb11 protein expression in livers of mice (n = 3;
bars represent densitometric quantification
normalized to albumin). All bars show mean ±
SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
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Golgi to the cytosol and plasma membrane (Kubitz et al., 2004).
Depletion of Kupffer cells by injection of mice with clodronate li-
posomes abrogated the effect of aspirin on hepatic Abcb11
expression, indicating that these cells serve as a major source
for LT and LX formation in vivo (Figure S6). So far, Alox5 was
thought to be critical for LT and LX generation. However, our lip-
idomic analyses in primary murine hepatocytes and in livers of
Alox5/ mice indicate that in the absence of Alox5 other en-
zymes may compensate the lack of this lipoxygenase. Interest-
ingly, this alternative pathway remains aspirin responsive, since
treatment of Alox5/mice with aspirin led to a further decrease
in LT levels (Figure S7), thus indicating the existence of a regu-
lated compensatory mechanism of LT and LX synthesis in liver
of mice.
In an effort to better understand the relative contributions of
the main lipoxygenases involved in LT and LX synthesis to
RCT in mice, we performed a series of loss-of-function experi-
ments. Studies in mice lacking Alox5 or Alox12/15 identified
Alox5 as the lipoxygenase with RCT-modifying properties. By
combining our mechanistic in vitro experiments with mediator
lipidomic profiling, our data suggest that in vivo the balance be-
tween LXs and LTsmodulates the expression of hepatic Abcb11,
i.e., when LX levels exceed LT levels. Surprisingly, Alox5/mice
did not show increased excretion of macrophage-derived ste-
rols, despite reduced plasma [3H]-cholesterol levels. This may
be due to lower biliary excretion of neutral sterols via Abcg5
and Abcg8 and/or increased intestinal absorption of neutral ste-
rols in Alox5/ mice, a prediction which will require further
studies to be clarified.
Finally, we tested LXmimetics in vivo for the following reasons:
first, LX mimetics are stable in circulation and may thus modu-
late hepatic expression of sterol receptors/transporters in a
favorable way; second, LXs have a proresolving function in
atherosclerosis. Taken together, these properties may confer
atheroprotective effects on LX mimetics. We found that stable
LXB4 analogs strongly induced hepatic expression of LDLr and796 Cell Metabolism 20, 787–798, November 4, 2014 ª2014 The Authorsaccordingly reduced plasma cholesterol
levels. To better understand how lipoxin
mimetics regulate LDLr expression in
liver of mice, further studies aimed at
investigating the regulation of known
LDLr-modifying machineries includingHMG-CoAr-, PCSK9-, and IDOL-dependent pathways, together
with the analysis of cholesterol-modulating miRNAs in livers
of LX-treated mice, are needed. Intriguingly, we found that
Abcb11 protein levels were reduced in livers of mice treated
with LX mimetics. From our lipidomic analyses we learned that
in vivo Abcb11 can be induced when (1) both LTs and LXs are
increased, and when (2) LXs remain unchanged and LTs are
reduced, whereas Abcb11 expression is unaltered when LXs
remain unchanged and LTs increase. These data indicate that
in the liver LX generation is tightly regulated and that LXs are
probably a more important regulator of Abcb11 than LTs. In
fact, our in vitro experiments showed that LXs induce Abcb11
only at low concentrations, whereas they decrease its expres-
sion when given at higher dosages. We thus conclude that LXs
may regulate Abcb11 with higher specificity than LTs and spec-
ulate that exogenously administered LXs could have critically
altered lipid mediator homeostasis in the liver, thereby
decreasing Abcb11 expression.
Our results support the notion that modulation of the AA me-
tabolome may be used to treat and prevent CAD, and may
explain how omega-6 PUFAs influence cholesterol homeostasis.
In humans, most PUFAs in the diet consist of the omega-6 type
including linoleic acid which is converted into the metabolically
important AA after consumption (Harris et al., 2009; Katan,
2009). Higher omega-6 PUFA levels were shown to improve in-
sulin resistance, to reduce the incidence of diabetes mellitus,
and to associate with lower blood pressure. Moreover, omega-
6 PUFAs were shown to lower plasma LDL-C and plasma total
cholesterol-to-HDL-C ratio (summarized in Harris et al., 2009).
These effects are believed to confer omega-6 PUFAs and espe-
cially AA with atheroprotective properties (Harris et al., 2009; Ka-
tan, 2009). Combined data from randomized trials, case-control
and cohort studies, and animal experiments indicate that the
consumption of at least 5%–10% of energy from omega-6
PUFAs reduces the cardiovascular risk (Harris et al., 2009),
which recently prompted the American Heart Association to
release a recommendation for dietary supplementation with
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Arachidonic Acid Metabolome and Cholesterolomega-6 PUFAs (Harris et al., 2009). Using a systematic, inter-
disciplinary approach, we were able to elucidate the relative
role of key players of the AA metabolism in whole-body choles-
terol homeostasis in humans and in mice.
To summarize, we show that pharmacological and genetic
modulation of the AA metabolome affects one major function
of HDL, namely RCT. Moreover, we show that the AA metabo-
lome is a conserved regulator of HDL-C in humans and in
mice, and identify LX mimetics (Maddox et al., 1998) as an
approach to reduce plasma LDL-C. However, it is appropriate
to issue certain caveats when trying to extrapolate mouse data
to humans, since mouse models have limitations for the
following reasons: mice have a different lipoprotein profile
when compared to humans, with HDL being the major lipopro-
tein fraction in plasma; they do not express cholesteryl ester
transfer protein in plasma; and they do not develop atheroscle-
rosis when fed a high-cholesterol diet. Although we cannot
directly extrapolate our data on Abcb11, SR-BI, and LDLr to hu-
man cholesterol metabolism, we definitively show that the AA
metabolome plays a physiological role in whole-body cholesterol
homeostasis and HDL function in mammals, paving the way for
the development of novel lipid-lowering drugs based on the
structure of AA metabolites and offering a novel therapeutic
strategy to counteract CAD in humans.
EXPERIMENTAL PROCEDURES
Human Genome-Wide Association Data
Genome-wide association data with HDL-C, LDL-C, and total cholesterol was
generated by the Global Lipids Genetics Consortium (GLGC) as previously
described (Teslovich et al., 2010): http://www.sph.umich.edu/csg/abecasis/
public/lipids2010/. The GLGC 2013 data set was recently published (Willer
et al., 2013): http://www.sph.umich.edu/csg/abecasis/public/lipids2013/.
Plots used in Figures 1, S1, and S2 were generated using LocusZoom (Pruim
et al., 2010).
Animal Studies
All animals were handled in strict accordance with good animal practice as
defined by the Austrian Authorities, and all animal work was approved by
the Austrian Animal Care and Use Committee (Bundesministerium fu¨r Wissen-
schaft und Forschung–BMWF). Mice were fed a standard chow diet (Ssniff). To
induce Cox I/II inhibition, mice were treated with drinking water containing
aspirin for 7 days, as described previously by our laboratory (Tancevski
et al., 2006). On a body-scale-adjusted scale, the amount of aspirin would
be equal to 360 mg per day if the animals weighed 60 kg (6 mg kg1 per
day) (Tancevski et al., 2006).
Mediator Lipidomics
LC-MS/MS-based lipidomic analyses were performed using a high-perfor-
mance liquid chromatography (HPLC) system (Waters UPLC) with a linear
ion trap quadrupole mass spectrometer (QTRAP5500; AB SCIEX) equipped
with an Acquity UPLC BEH C18 column (Waters) as described (Arita, 2012;
Morita et al., 2013). MS/MS analyses were conducted in negative ion mode,
and fatty acid metabolites were identified and quantified by multiple reaction
monitoring (MRM). Different tissue isolation procedures and/or different age
or body weight of mice could cause differences in the basal levels of AA me-
tabolites. Thus, lipid mediator levels shown in Figures 3B, 5F, 6F, and S7
cannot be directly compared.
Statistical Analysis
Statistical analysis was carried out with a SPSS statistical package (IBM). We
determined significance by unpaired two-tailed Student’s t test, or by one-way
ANOVAwhenmore than two groups were compared. p < 0.05 was considered
statistically significant.Cell MSUPPLEMENTAL INFORMATION
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